|
| | Study design | Number of patients | Number of ERCPs | Age (years) | Male n (%) | PSC characteristics | Relevant comorbidities |
|
| Adler (2016) | Retrospective cohort | | PSC: 376
Non-PSC: 162 | | | Cirrhosis: 376 (100%) | |
| Alkhatib (2011) | Retrospective cohort | PSC: 75 | PSC: 185 | Mean 50.1 (range 15–85) | 58 (77%) | Cirrhosis: 6 (8%) | Autoimmune hepatitis: 2 (3%)
IBD: 42 (55%) |
| Baluyut (2001) | Retrospective cohort | 63 | | Mean 46.7 ± 15.8 | 38 (60%) | Baseline cholangitis: 31 (49%)
Dominant stricture: 63 (100%) | |
| Bangarulingam (2009) | Retrospective cohort | PSC: 168
Non-PSC: 981 | PSC: 308
Non-PSC: 1268 | PSC mean: 48 ± 15
Non-PSC mean: 60 ± 19 | PSC: 111 (66.1%)
Non-PSC: 440 (44.9%) | Portal hypertension: 53 (32%) | |
| Cazzagon (2019) | Retrospective cohort | PSC: 31 | PSC: 63 | Median: 36 (27–52) | 20 (65%) | Baseline cholangitis: 5 (16%)
Cirrhosis: 10 (32%)
Dominant stricture: 31 (100%) | |
| Enns (2003) | Retrospective cohort | PSC: 104 | PSC: 204 | Mean 45 ± 13.6 | 66 (63%) | Dominant stricture: 69 (66%) | IBD: 94 (53%) |
| Etzel (2008) | Retrospective cohort | PSC: 30
Non-PSC: 45 | PSC: 85
Non-PSC: 70 | PSC mean: 44.5 ± 2.1 (range 24–69)
Non-PSC mean: 56.5 ± 2.4 (range 28–85) | PSC: 22 (73.3%)
Non-PSC: 28 (62.2%) | Dominant stricture: 63 (76%)
Mean duration of PSC: 4.55 years (range 0–15) | |
| Gluck (2008) | Retrospective cohort | PSC: 106 | PSC: 317 | Mean: 47 (range 15–86) | 65 (61%) | Cirrhosis: 41 (39%) | Cholangiocarcinoma: 13 (12%)
IBD: 86 (74%)
Liver transplant: 7 (7%) |
| Gotthardt (2010) | Prospective cohort | PSC: 96 | PSC: 500 | Mean: 37.4 ± 1.4 (range 17–77) | 69 (71.9%) | Dominant stricture: 97 (100%) | Cholangiocarcinoma: 6 (6%)
Liver transplant: 22 (23%) |
| Ismail (2012) | Retrospective cohort | PSC: 441 | | Median: 38 (range 5–80) | 238 (54%) | Prior biliary sphincterotomy: 147 (38%) | |
| Kaya (2001) | Retrospective cohort | Balloon dilation: 34
Balloon dilation and stenting: 14 | Balloon dilation: 73
Balloon dilation and stenting: 80 | Balloon dilation median: 50.5 (range 21–72)
Balloon dilation and stenting median: 44 (range 18–78) | Balloon dilation: 22 (64.7%)
Balloon dilation and stenting: 18 (48.6%) | Dominant stricture: 71 (100%) | IBD: 45 (63%) |
| Koskensalo (2020) | Retrospective case-control | Diclofenac: 378
No diclofenac: 553 | Diclofenac: 1000
No diclofenac: 1000 | Diclofenac median: 40 (range 16–73)
No diclofenac median: 39 (16–79) | Diclofenac: 238 (63%)
No diclofenac: 327 (59.1%) | | |
| Navaneethan (2015) | Retrospective cohort | PSC: 294 | PSC: 657 | Median: 47 (range 12–85) | 203 (69%) | Prior biliary sphincterotomy: 64 (21.8%) | |
| Navaneethan (2017) | Prospective cohort with the historical control group | Group 1 (control): 156
Group 2 (bile aspiration before contrast injection): 46 | Group 1: 156
Group 2: 46 | Group 1 mean: 43.77 ± 18.9
Group 2 mean: 54.96 ± 15.8 | Group 1: 104 (66.7%)
Group 2: 27 (58.7%) | Dominant stricture: 47 (23%)
Prior biliary sphincterotomy: 57 (28%)
Prior pancreatic sphincterotomy: 1 (0.5%) | |
| Parlak (2004) | Retrospective cohort | PSC: 16 | PSC: 58 | Mean: 35 ± 11.2 | 10 (62.5%) | Dominant stricture: 16 (100%) | IBD: 10 (63%) |
| Peiseler (2018) | Retrospective cohort | PSC: 208 | PSC: 663 | Mean: 45.3 (range 25–79) | 134 (64.4%) | Cirrhosis: 138 (66%) | IBD: 128 (62%)
Immunosuppressed: 94 (45%) |
| Ponsioen (2018) | Randomized controlled trial | | Balloon dilation: 30
Stenting: 33 | Mean: 40 ± 14 | 45 (69.2%) | Dominant stricture: 65 (100%)
Median disease duration: 4–7 years
Prior sphincterotomy: 25 (39%) | IBD: 50 (78%) |
| Rupp (2019) | Retrospective cohort | 286 | >1800 | Median: 33.3 | 209 (73.1%) | Dominant stricture: 179 (63%) | IBD: 209 (73%) |
| Thiruvengadam (2016) | Retrospective cohort | Rectal indomethacin: 91
No rectal indomethacin: 90 | | | | | |
| Von Seth (2015) | Retrospective cohort | PSC: 141
Non-PSC: 8791 | PSC: 141
Non-PSC: 8791 | PSC mean: 45 ± 16
Non-PSC mean: 69 ± 16 | PSC: 87 (62%)
Non-PSC: 3868 (44%) | Prior sphincterotomy: 26 (18%) | |
|
